Monika E. Hegi
Impact in
- Genetics top 0.01%
- Glioma Diagnosis and Treatment
- Cancer Research top 0.1%
- Cancer, Hypoxia, and Metabolism
- MicroRNA in disease regulation
- Cancer Genomics and Diagnostics
Papers in
- Genetics 103
- Glioma Diagnosis and Treatment 103
-
- Epigenetics and DNA Methylation 29
- Histone Deacetylase Inhibitors Research 17
- Co-authors
- Roger Stupp (69 shared papers)Michael Weller (34 shared papers)Thierry Gorlia (24 shared papers)Marie‐France Hamou (23 shared papers)Nicolas de Tribolet (8 shared papers)J. Gregory Cairncross (4 shared papers)R.O. Mirimanoff (4 shared papers)Johannes A. Hainfellner (8 shared papers)
- Journals
- Neuro-Oncology (20 papers)Journal of Clinical Oncology (19 papers)Oncogene (6 papers)Cancer Research (5 papers)European Journal of Cancer (5 papers)
- Partner nations
- SwitzerlandUnited StatesGermany
In The Last Decade
Monika E. Hegi
154 papers receiving 20.7k citations
Monika E. Hegi's Hit Papers
Peers
Comparison fields: 5 of 144
- Genetics 11.8k
- Cancer Research 4.8k
- Oncology 3.5k
- Molecular Biology 7.9k
- Pulmonary and Respiratory Medicine 3.1k
Countries citing papers authored by Monika E. Hegi
This map shows the geographic impact of Monika E. Hegi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monika E. Hegi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monika E. Hegi more than expected).
Fields of papers citing papers by Monika E. Hegi
This network shows the impact of papers produced by Monika E. Hegi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monika E. Hegi. The network helps show where Monika E. Hegi may publish in the future.
Co-authors
The 25 scholars most cited alongside Monika E. Hegi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 155 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma Hit paper breakdown → | 2005 | 5292 |
| 2 | Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial Hit paper breakdown → | 2012 | 874 |
| 3 | Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial Hit paper breakdown → | 2013 | 749 |
| 4 | Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity Hit paper breakdown → | 2008 | 662 |
| 5 | Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells Hit paper breakdown → | 2020 | 649 |
| 6 | Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide Hit paper breakdown → | 2004 | 634 |
| 7 | MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Hit paper breakdown → | 2009 | 579 |
| 8 | Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma Hit paper breakdown → | 2008 | 567 |
| 9 | Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma Hit paper breakdown → | 2014 | 452 |
| 10 | In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. | 1993 | 415 |
| 11 | 2007 | 414 | |
| 12 | MGMT testing—the challenges for biomarker-based glioma treatment Hit paper breakdown → | 2014 | 402 |
| 13 | 2007 | 399 | |
| 14 | 1992 | 389 | |
| 15 | Glioma epigenetics: From subclassification to novel treatment options Hit paper breakdown → | 2017 | 380 |
| 16 | 2011 | 365 | |
| 17 | 2010 | 343 | |
| 18 | 2006 | 298 | |
| 19 | 2018 | 226 | |
| 20 | 2012 | 224 |
About Monika E. Hegi
Monika E. Hegi is a scholar working on Genetics, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine and Oncology, having authored 155 papers that have together received 21.0k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (103 papers), Epigenetics and DNA Methylation (29 papers), Brain Metastases and Treatment (20 papers), Histone Deacetylase Inhibitors Research (17 papers), Cancer Genomics and Diagnostics (15 papers), Cancer-related Molecular Pathways (11 papers), Cancer, Hypoxia, and Metabolism (10 papers) and Neuroblastoma Research and Treatments (9 papers). The work is most often cited by research in Genetics (11.8k citations), Cancer Research (4.8k citations), Oncology (3.5k citations), Molecular Biology (7.9k citations) and Pulmonary and Respiratory Medicine (3.1k citations). Monika E. Hegi has collaborated with scholars based in Switzerland, United States and Germany. Frequent co-authors include Roger Stupp, Michael Weller, Thierry Gorlia, Marie‐France Hamou, Nicolas de Tribolet, J. Gregory Cairncross, R.O. Mirimanoff, Johannes A. Hainfellner, Annie‐Claire Diserens and Martin J. van den Bent. Their work appears in journals such as Neuro-Oncology, Journal of Clinical Oncology, Oncogene, Cancer Research and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.